DENTSPLY SIRONA Inc. $XRAY Shares Sold by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC cut its stake in DENTSPLY SIRONA by 57.3% in Q4, selling 107,971 shares and leaving 80,560 shares valued at about $997,000.
• Insider purchases continued: Director Gregory T. Lucier bought 15,000 shares at $12.45 and Director James D. Forbes bought 5,000 shares at $12.48, contributing to 70,000 shares purchased by insiders over the past 90 days.
• XRAY reported Q EPS of $0.27 (missed by $0.01) with revenue of $961M (beat expectations), set FY2026 guidance of $1.40–$1.50 EPS, and carries an average analyst rating of "Hold" with a $14.42 consensus target while trading around $11.64.

Wealth Enhancement Advisory Services LLC cut its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 57.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,560 shares of the medical instruments supplier's stock after selling 107,971 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in DENTSPLY SIRONA were worth $997,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in DENTSPLY SIRONA by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier's stock valued at $279,263,000 after purchasing an additional 869,566 shares during the last quarter. AQR Capital Management LLC boosted its holdings in DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in DENTSPLY SIRONA by 0.9% in the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier's stock valued at $129,445,000 after purchasing an additional 92,868 shares during the last quarter. State Street Corp boosted its holdings in DENTSPLY SIRONA by 5.5% in the 2nd quarter. State Street Corp now owns 7,099,906 shares of the medical instruments supplier's stock valued at $113,868,000 after purchasing an additional 369,876 shares during the last quarter. Finally, Armistice Capital LLC boosted its holdings in DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier's stock valued at $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 15,000 shares of the business's stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average cost of $12.45 per share, with a total value of $186,750.00. Following the purchase, the director directly owned 65,000 shares in the company, valued at approximately $809,250. This represents a 30.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James D. Forbes acquired 5,000 shares of the company's stock in a transaction on Monday, March 9th. The stock was purchased at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at approximately $124,800. The trade was a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 70,000 shares of company stock worth $956,437. 0.50% of the stock is owned by insiders.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $11.64 on Tuesday. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $17.18. The firm's 50 day moving average price is $12.45 and its 200 day moving average price is $12.11. The company has a market cap of $2.33 billion, a P/E ratio of -3.88, a PEG ratio of 1.37 and a beta of 0.99. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $961.00 million for the quarter, compared to analysts' expectations of $926.40 million. During the same period in the previous year, the company earned $0.26 earnings per share. DENTSPLY SIRONA's quarterly revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, research analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XRAY has been the topic of several recent analyst reports. Zacks Research upgraded shares of DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a report on Monday, March 2nd. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, February 3rd. Wells Fargo & Company boosted their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 27th. Barclays initiated coverage on shares of DENTSPLY SIRONA in a report on Monday, December 8th. They issued an "underweight" rating and a $12.00 target price on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $14.42.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.